ClinVar Miner

Submissions for variant NM_000465.4(BARD1):c.808G>T (p.Glu270Ter)

dbSNP: rs1060501288
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000565570 SCV000665785 pathogenic Hereditary cancer-predisposing syndrome 2021-09-16 criteria provided, single submitter clinical testing The p.E270* pathogenic mutation (also known as c.808G>T), located in coding exon 4 of the BARD1 gene, results from a G to T substitution at nucleotide position 808. This changes the amino acid from a glutamic acid to a stop codon within coding exon 4. This alteration was detected in a cohort of 8085 consecutive unselected Chinese breast cancer patients who underwent multi-gene panel testing (Sun J et al. Clin Cancer Res, 2017 Oct;23:6113-6119). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Invitae RCV000796390 SCV000935902 pathogenic Familial cancer of breast 2023-11-01 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Glu270*) in the BARD1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BARD1 are known to be pathogenic (PMID: 20077502, 21344236). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 28724667). ClinVar contains an entry for this variant (Variation ID: 481415). For these reasons, this variant has been classified as Pathogenic.
Baylor Genetics RCV000796390 SCV004217323 pathogenic Familial cancer of breast 2022-07-19 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV000796390 SCV004931414 pathogenic Familial cancer of breast 2024-01-23 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.